Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
38240
CAS Number:
112887-68-0
Raltitrexed
Purity:
≥ 98% (HPLC)
Synonym(s):
N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid, ICI-D-1694
Hazmat
Documents
$334.10 /50MG
Pack Size Availability Price
Request Bulk Quote
Product Information
Synonyms
N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid, ICI-D-1694
CAS Number
112887-68-0
Purity
≥ 98% (HPLC)
Molecular Formula
C21H22N4O6S
Molecular Weight
0
MDL Number
MFCD00864168
PubChem ID
135450461
Melting Point
176 °C (dec.)
Appearance
White to light yellow powder to crystal
Optical Rotation
[a]D20 = -15 to -20 ° (C=1 in MeOH)
Conditions
Store at < 0 °C
General Information
Synonyms
N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid, ICI-D-1694
CAS Number
112887-68-0
Purity
≥ 98% (HPLC)
Molecular Formula
C21H22N4O6S
Molecular Weight
0
MDL Number
MFCD00864168
PubChem ID
135450461
Melting Point
176 °C (dec.)
Appearance
White to light yellow powder to crystal
Optical Rotation
[a]D20 = -15 to -20 ° (C=1 in MeOH)
Conditions
Store at < 0 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
Yes
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Raltitrexed is widely utilized in research focused on

  • Cancer Treatment: This compound is primarily used as an anti-cancer agent, particularly in the treatment of colorectal cancer. It acts as a thymidylate synthase inhibitor, disrupting DNA synthesis in rapidly dividing cancer cells.
  • Pharmaceutical Development: Raltitrexed serves as a critical reference compound in the development of new anti-cancer drugs. Researchers study its mechanisms to design more effective therapies with fewer side effects.
  • Combination Therapies: It is often used in combination with other chemotherapeutic agents to enhance treatment efficacy. This synergistic approach can improve patient outcomes in various cancer types.
  • Clinical Trials: Raltitrexed is frequently involved in clinical trials aimed at evaluating new treatment regimens. Its established profile helps researchers assess the effectiveness of novel therapeutic strategies.
  • Research on Drug Resistance: Scientists study Raltitrexed to understand mechanisms of drug resistance in cancer cells. Insights gained can lead to the development of strategies to overcome resistance and improve treatment success.

Citations